Tech Company Financing Transactions
NeurogesX Funding Round
Alta Partners, Arch Venture Partners and Mitsubishi Corporation invested in a $20 million funding round for NeurogesX. The round closed on 12/1/2005.
Transaction Overview
Company Name
Announced On
12/1/2005
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This financing enables us to complete our clinical development programs for Transacin in both postherpetic neuralgia (PHN) and HIV-associated neuropathy (HIV-AN).
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
999 Baker Way 200
San Mateo, CA 94404
USA
San Mateo, CA 94404
USA
Phone
Website
Email Address
Overview
NeurogesX is a privately held specialty pharmaceutical company focusing on the development novel treatments for improved relief of neuropathic pain and improved quality of life for neuropathic pain patients using advanced neuroscience insights and innovative delivery technologies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ronald Martell
Chief Financial Officer
Stephen Ghiglieri
Chief Medical Officer
Stephen Peroutka
Browse more venture capital transactions:
Prev: 11/30/2005: AkaRx venture capital transaction
Next: 12/1/2005: Alimera Sciences venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs